<DOC>
	<DOCNO>NCT02719327</DOCNO>
	<brief_summary>The number Americans diagnose Alzheimer 's disease ( AD ) expect triple 2050 . Compared general population , Veterans great risk AD , likely part due increase incidence traumatic brain injury , post-traumatic stress disorder , depression , vascular-related health issue . Based available data , 423,000 new case AD anticipate Veterans 2020 . Thus , discovery effective therapy prevent delay onset AD Veterans critical . The goal study evaluate efficacy purified form omega-3 fatty acid eicosapentaenoic acid ( EPA ) call icosapent ethyl ( IPE ) , improve brain blood flow , spinal fluid marker AD pathology , cognitive performance middle-aged , cognitively-healthy Veterans increase risk AD . If IPE delay onset AD even 5 year , incidence AD would reduce 50 % population could profound effect Veteran quality life healthcare cost .</brief_summary>
	<brief_title>Brain Amyloid Vascular Effects Eicosapentaenoic Acid</brief_title>
	<detailed_description>The propose study proof-of-concept , randomize , placebo-controlled , double-blind , parallel-group clinical trial assess efficacy 18 month icosapent ethyl ( IPE ) therapy magnetic resonance imaging ( MRI ) , cerebrospinal fluid ( CSF ) , cognitive biomarkers AD 150 cognitively-healthy Veterans age 50-70 year increase risk develop AD due parental history disease increase prevalence apolipoprotein E4 ( APOE4 ) allele . The overarch goal trial ass whether icosapent ethyl beneficially affect intermediate physiological measure associate onset AD order evaluate whether large , multi-site , longer-duration Alzheimer 's prevention trial warrant assess definitive clinical outcome . The propose study aim : 1 ) investigate effect 18 month IPE vs. placebo regional cerebral blood flow measure arterial spin-labeling MRI ; 2 ) determine impact 18 month IPE vs. placebo CSF biomarkers AD pathology ; 3 ) evaluate effect 18 month IPE vs. placebo cognitive performance .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
	<criteria>Parental history Alzheimer 's disease United States Veteran eligible VA care Age 5070 year , inclusive Cognitively healthy Dementia mild cognitive impairment screen evaluation Current use cholesterollowering medication fish oil supplement Active liver disease AST ALT great twice upper limit normal Elevated creatine kinase great twice upper limit normal Prior adverse reaction statin fish oil Pregnant , nursing , pregnancy plan Use medication interact icosapent ethyl Current use anticoagulant Known hypersensitivity fish and/or shellfish Current use investigational drug History significant atherosclerotic cardiovascular disease diabetes mellitus Lowdensity lipoprotein ( LDL ) cholesterol &gt; =190 mg/dL &lt; 80 mg/dL Triglycerides &gt; = 500 mg/dL Creatinine &gt; 1.8 mg/dL Previous lumbar surgery contraindication lumbar puncture Claustrophobia require sedation MRI Pacemaker contraindication MRI Consumption &gt; 200 mg per day omega3 fatty acid diet</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Cerebrospinal fluid</keyword>
	<keyword>brain blood flow</keyword>
	<keyword>cognition</keyword>
	<keyword>icosapent ethyl</keyword>
	<keyword>Vascepa</keyword>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>eicosapentaenoic acid</keyword>
</DOC>